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Abstract
Background: Three diagnostic criteria have been proposed used for invasive pulmonary aspergillosis (IPA) diagnosis,
namely EORTC/ MSG criteria, Bulpa criteria and intensive care unit (ICU) criteria. The Bulpa criteria were proposed to
diagnose IPA in chronic obstructive pulmonary disease (COPD) patients specially. Our aim is to verify that whether the
Bulpa criteria are the most suitable for diagnosing probable IPA in critically ill COPD patients compared with the other
two criteria.
Methods: We included critically ill COPD patients admitted to the ICU from April 2006 to August 2013. Patients were
classified into four populations: population one (n1 = 59) comprised all included patients; population two (n2 = 24)
comprised patients with positive mycological findings (both positive cultures and positive serologic tests); population
three (n3 = 18) comprised patients with positive lower respiratory tracts (LRTs) isolation; and population four (n4 = 5)
comprised proven IPA patients with histopathology. Patients in four groups were diagnosed as probable IPA using
three criteria respectively, and the “diagnostic rate” of each criteria were compared with each other. Then, the reasons
for differences in “diagnostic rate” were analyzed in population two. Finally, the modified Bulpa criteria were proposed.
Results: Bulpa criteria yielded the highest “diagnostic rate” of probable IPA followed by the ICU criteria, while the
EORTC/ MSG criteria provided the lowest rates in four populations (the “diagnostic rate” of probable IPA was 33.9%, 16.
9% and 6.8% in population one, p = 0.001; 83.3%, 41.7% and 16.7% in population two, p < 0.001; 100%, 55.6% and 22.
2% in population three, p < 0.001; 100%, 60% and 20% in population four, p = 0.036). The reasons for the highest
“diagnostic rate” by Bulpa criteria were its less strict requirements regarding the doses/courses of steroid use and
typical computed tomography (CT) findings. Finally, the modified Bulpa criteria for probable IPA were proposed for
critically ill COPD patients admitted to ICU, mainly involving revised interpretations of microbiological findings.
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Conclusions: Among the existing three criteria, the Bulpa criteria are the most suitable for diagnosing probable IPA in
critically ill COPD patients admitted to ICU. A modified criteria maybe proposed for better diagnosis,and its clinical validity
need to be verified in future studies.
Keywords: Invasive pulmonary aspergillosis, Chronic obstructive pulmonary disease, Bulpa criteria, EORTC/ MSG criteria,
ICU criteria
Background
Chronic obstructive pulmonary disease (COPD) has
been recognized as a potential risk factor of invasive pul-
monary aspergillosis (IPA) [1–3]. The average mortality
of IPA in COPD patients has been found to be as high
as 50-100% [1, 4, 5], and is especially in patients with de-
layed diagnosis.
Tremendous challenges in early diagnosis of IPA
existed among specialists in pulmonary and critical care
medicine. Therefore, appropriate diagnostic criteria are
crucial for IPA at the early stage.
Three diagnostic criteria have been proposed used for
IPA diagnosis. The EORTC/ MSG criterion was
proposed by a consensus group of the European
Organization for the Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group
(EORTC) and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (MSG) in the
year 2002 for use with haematological patients, and this
criteria were revised in 2008 [6, 7]. Bulpa proposed an-
other set of criteria in 2007 specifically for use with
COPD patients in respiratory ward [8]. According to
both sets of criteria, IPA is categorized as proven, prob-
able or possible. A third set of criteria was put forwarded
by Vandewoude use with intensive care unit (ICU) pa-
tients, with an entry criterion of positive lower respira-
tory tract (LRT) specimens for Aspergillus; this set
categorized IPA as proven or putative, where putative
IPA could be regarded as probable IPA in the first two
criteria sets mentioned above [9, 10]. Since the critically
ill COPD patients admitted to ICU had their particular
characteristics which were huge different with severe im-
munocompromised patients, we made a clinical assump-
tion that Bulpa criteria are the most suitable for
diagnosing probable IPA in critically ill COPD patients
admitted to ICU compared with the other two criteria.
Methods
Study population and inclusion criteria
All of the patients were admitted to our respiratory ICU
(RICU) due to respiratory failure from April 2006 to
August 2013.
Inclusion criteria
We included patients based on the following criteria:
1) Older than 50 years old.
2) Severe COPD with a pulmonary functional level of
stage III or IV according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD). We
made the corresponding changes based on the updated
GOLD guidelines [11–13].
3) At least one computed tomography (CT) recorded
during their hospitalization. CT(s) were provided
within 1 week prior to admission to the RICU.
Exclusion criteria
We excluded patients based on the following criteria:
1) Patients with solid organ transplantation (SOT) and
haematopoietic stem cell transplantation (HSCT),
which included allergenic and autologous HSCT.
2) Patients with neutropenia, blood system diseases,
malignant tumors and human immunodeficiency
virus (HIV) infection.
3) Patients who accepted a high dosage of
immunosuppressant because of connective tissue
disease (CTD) in the previous 3 months.
Diagnostic criteria
Definitions for proven IPA
Items required for proven IPA were same in the three
criteria [7–10].
Microscopic analysis of sterile material: histopatho-
logical, cytopathological, or direct microscopic examin-
ation of a specimen obtained by needle aspiration or
sterile biopsy in which hyphae are observed and are
accompanied by evidence of associated tissue damage.
Culture on sterile material: recovery of Aspergillus by
culturing of a specimen obtained by lung biopsy.
Definitions for Probable/Putative IPA
The definition for probable/ putative IPA can be con-
cluded based on the following three types of informa-
tion: host factors, clinical data and microbiological
findings.
The following is a brief description of the three parts
in each diagnostic criterion (Table 1). The main differ-
ences among three criteria were marked with italic and
underline.
Additional instructions in EORTC/ MSG Criteria [7]:
Huang et al. BMC Infectious Diseases  (2017) 17:209 Page 2 of 9
Because of the exclusion criteria adopted in our study,
our patients may only satisfy condition iii).
Critically ill COPD patients who met host factor iii),
one of the clinical data and one of the microbiological
findings were diagnosed as probable IPA.
Additional instructions in Bulpa Criteria [8]:
In our hospital, the detection of serum antibody or
precipitin for A. fumigatus was unavailable.
The cut-off values of the serum galactomannan (GM)
and broncho-alveolar lavage fluid (BALF) GM tests are
0.5 ng/ml and 0.8 ng/ml [14, 15], respectively. Serum
GM levels greater than 0.5 ng/ml and BALF GM levels
greater than 0.8 ng/ml were defined as positive results.
Critically ill COPD patients who met all host factors,
all clinical criteria and one of the microbiological find-
ings were diagnosed as probable IPA.
Additional instructions in ICU Criteria [9, 10]
If the patients did not present any host factors, a
semi-quantitative Aspergillus-positive culture of BALF
(+ or ++), without bacterial growth together but with
a positive cytological smear showing branching hy-
phae is considered as alternative. Unfortunately, the
semi-quantitative Aspergillus culture of BALF was not
routinely available at our institution during the study
period.
The same as the EORTC criteria, because of the exclu-
sion criteria adopted in our study, our patients may only
present condition iii).
Critically ill COPD patients who met host factor iii),
all clinical data and microbiological findings were diag-
nosed as putative IPA.
Data collection and analysis
Patient characteristics, including age, sex, the usage, dos-
age and duration of steroids prior toadmission to the
RICU, microbiological examinations (including cultures
of the sputum, endotracheal aspiration (ETA) and BALF,
and serum GM and BALF GM tests), chest radiological
Table 1 Brief descriptions of each diagnostic criteria
EORTC/ MSG Criteria Bulpa Criteria ICU Criteria
Host factors i) A recent history of neutropenia (<0.5*109
neutrophils/L for more than 10 days) that is
temporally related to the onset of fungal disease.
ii) Receipt of an allogeneic stem cell transplant.
iii) Prolonged use of corticosteroids at a mean
minimum dose of 0.3 mg/kg/day of a prednisone
equivalent for more than 3 weeks.
iv) Treatment with other recognized T cell
immunosuppressants, such as cyclosporine,
TNF-α blockers, specific monoclonal antibodies
or nucleoside analogues during the previous
90 days.
v) Inherited severe immunodeficiency.
i) Patients with a pulmonary
functional level of stage III or IV
according to the GOLD guidelines.
ii) Patients treated with steroids, with
no strict requirement regarding the
usage, dosage or duration.
i) Neutropenia (absolute neutrophil count
< 500/mm3) preceding or at the time of
ICU admission.
ii) Underlying haematological or oncological
malignancy treated with cytotoxic agents.
iii) Glucocorticoid treatment (prednisone
equivalent, >20 mg/d).
iv) Congential or acquired immunodeficiency.
Clinical data Patients must have subjected to at least one CT
scan and must exhibit 1 of the following 3 signs:
i) Dense, well-circumscribed lesion(s) with or
without a halo sign.
ii) An air-crescent sign.
iii) A cavity.
i) Patients with recent exacerbation
of dyspnea despite the administration
of appropriate antibiotics.
ii) Patients with progressive deterioration
of chest imaging findings
(within three months)
i) One of the following compatible signs
or symptoms:
① Fever refractory to at least three days
of appropriate antibiotic therapy.
② Recrudescent fever after a period of
defervescence of at least 48 h while still
on antibiotics and without other apparent
cause.




⑦ Worsening respiratory insufficiency
despite appropriate therapy and ventilator
support.




i) Positive culture and/or microscopy result
for Aspergillus from the lower respiratory
tracts (LRTs).
ii) Positive serum or bronchoalveolar lavage
fluid (BALF) galactomannan (GM) tests.
i) Positive culture and/or microscopy
findings for Aspergillus from the LRTs.
ii) Positive serum antibody test for
A. fumigatus (including precipitin).
iii) Two consecutive positive serum
GM tests.
Positive culture for Aspergillus from the LRTs.
Note: We concluded each criteria as three parts, namely the host factors, clinical data and microbiological findings and marked the main differences among three
criteria italic and underline. EORTC/MSG European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study Group; ICU Intensive Care Unit; TNF-α: Tumor Necrosis Factor-α; CT Computed Tomography;
CXR Chest X Ray; LRT Lower respiratory tract; BALF Bronchoalveolar Lavage Fluid; GM Galactomannan
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data (chest X rays (CXRs) and CT scans) and clinical
outcomes were collected.
Two experienced respiratory physicians and a radiolo-
gist who were not aware of the clinical outcomes of the
patient analysed the radiological data.
Methods for population divisions
All patients were classified into four populations. The
scope of each group gradually reduced.
Population one comprised all included COPD patients;
population two comprised patients with positive myco-
logical findings (both positive cultures and positive sero-
logic tests); population three comprised patients with
the positive LRTs isolation, which including sputum,
ETA and BALF; and population four comprised proven
cases of IPA based on histopathology.
Usually, the validity of diagnostic criteria is assessed
according to a gold standard, which depends on the use
of biopsy or necropsy. However, it was difficult to obtain
tissue specimen for critically ill COPD patients; there-
fore, we evaluated the “diagnostic rate” of three criteria
in different populations, and verified the result based on
a proven IPA population.
Patients from each population were diagnosed as
probable/ putative IPA using the above criteria, and the
“diagnostic rate” were compared among them. Patients
who did not fall into the probable/ putative IPA group
were considered as non-classifiable. The reasons for dif-
ferences in the “diagnostic rate” among the three criteria
were then analysed in population two (the population
with positive mycological findings). Finally, the modified
Bulpa criteria for probable IPA in critically ill COPD pa-
tients who have been admitted to ICU were proposed.
Statistical analysis
Our data were categorical variables; therefore, compara-
tive analyses were performed using a Pearson Chi-Square
(x2 test). For sample sizes of less than 40 or theoretical
frequencies (T) of less than 1, Fisher’s Exact Test was
used. P values < 0.05 were considered to indicate statistical
significance.
Results
From April 2006 to August 2013, 171 COPD patients
were admitted to the RICU because of respiratory fail-
ure. The numbers of patients who suffered from malig-
nancy, used a high doses of immunosuppressant in the
previous 3 months or for whom integrated radiological
imaging was not available were 3,6,2 and 101, respect-
ively; these patients were excluded from the study. 59
patients who met the inclusion criteria were enrolled.
All 59 critically ill COPD patients were classified into
four populations according to the previously described
methods. Population one included all 59 critically ill
COPD patients; population two included 24 patients
with positive mycological findings (both positive cultures
and positive serologic tests); population three included
18 patients with positive LRTs isolation; and population
four included 5 proven IPA cases based on bronchial
mucosal biopsy (Fig. 1).
General information
The history of steroids use, typical CT manifestations
and microbiological findings of the patients were pro-
vided in Additional file 1.
Estimate of the “ Diagnostic rate” for the three criteria in
each population
The patients in the four populations were diagnosed as
probable/ putative IPA using the Bulpa criteria, ICU cri-
teria and EORTC/ MSG, which were recorded in Table 2.
The respect “diagnostic rates” were 33.9%, 16.9% and
6.8% in population one, p = 0.001; 83.3%, 41.7% and
16.7% in population two, p < 0.001; 100%, 55.6% and
22.2% in population three, p < 0.001; 100%, 60% and 20%
in population four, p = 0.036. The Bulpa criteria resulted
in the highest “diagnostic rate” of probable IPA, followed
by the ICU criteria and the EORTC/ MSG criteria, in
that order; this trend was confirmed by population four
(the proven IPA patients).
Analysis of the reasons for the non-classification of patients
by each set of diagnostic criteria
The findings regarding “diagnostic rate” followed the
trend: Bulpa criteria, ICU criteria and EORTC/ MSG cri-
teria; therefore, we attempted to determine the reasons
for these differences by comparing any two criteria in
population two.
Comparison between EORTC/ MSG criteria and Bulpa criteria
We found that all probable IPA diagnosed by the
EORTC criteria were also diagnosed by the Bulpa cri-
teria; 16 (80%) patients who were not classified by
EORTC/ MSG could be diagnosed as probable IPA by
the Bulpa criteria, and the remaining 4 (20%) patients
remained non-classified even based on the Bulpa
criteria (Fig. 2).
Comparison between ICU criteria and Bulpa criteria
We found that all cases that were diagnosed as probable
IPA by the ICU criteria were also diagnosed by the
Bulpa criteria; 10 (71.4%) cases that were not classified
by ICU were diagnosed as probable IPA by the Bulpa
criteria, and the remaining 4 (28.6%) patients remained
non-classified even based on the Bulpa criteria (Fig. 3).
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Comparison between EORTC/ MSG criteria and ICU criteria
We found that only 1 (25%) case that was diagnosed as
probable IPA based on the EORTC/ MSG criteria was di-
agnosed by the ICU criteria, and the remaining 3 (75%)
cases were not classified; 9 (45%) cases that were not clas-
sified by EORTC were diagnosed as probable IPA based
on the ICU criteria, and the remaining 11 (55%) patients
remained non-classified by the ICU criteria (Fig. 4).
The reason underlying the non-classification of patients by
the EORTC/ MSG criteria
Among 24 patients with positive mycological findings,
only 4 were diagnosed as probable IPA cases; the non-
classification of 20 patients was attributed to the strict
requirements regarding the dosage and duration of ster-
oid use and the typical CT findings (Table 3).
The reason underlying the non-classification of patients by
the Bulpa criteria
Among 24 patients with positive mycological findings,
20 were diagnosed as probable IPA cases; the non-
classification of the remaining 4 patients was attributed
to the lack of consecutive BALF GM in the mycological
findings of the Bulpa criteria (Table 3).
The reason underlying the non-classification of patients by
the ICU criteria
Among 24 patients with positive mycological findings,
10 were diagnosed as putative IPA cases; the non-
classification of the remaining 14 patients was attributed
to the strict requirements regarding the dosage of ster-
oid use and the necessity for positive LRT cultures as an
entry criterion (Table 3).
Fig. 1 All 59 patients were classified into four populations. Population one comprised all 59 included patients; population two comprised 24 patients
with positive mycological findings (both positive cultures and positive serologic tests); population three comprised 18 patients with the positive LRTs
isolation; and population four comprised 5 proven cases of IPA based on histopathology
Table 2 The “ Diagnostic rate” in different populations according to three criteria
Diagnostic rate
n (%)
Bulpa Criteria ICU Criteria EORTC/MSG Criteria P value
Population one
(n = 59)
20 (33.9) 10 (16.9) 4 (6.8) 0.001*
Population two
(n = 24)
20 (83.3) 10 (41.7) 4 (16.7) <0.001*
Population three
(n = 18)
18 (100) 10 (55.6) 4 (22.2) <0.001*
Population four
(n = 5)
5 (100) 3 (60) 1 (20) 0.036*
Note: Population one: all included COPD patients; population two: patients with positive mycological findings; population three: patients with positive lower
respiratory tracts (LRTs) isolation; population four: proven IPA patients. The “diagnostic rate” of probable IPA were 33.9%, 16.9% and 6.8% in population one,
p = 0.001; 83.3%, 41.7% and 16.7% in population two, p < 0.001; 100%, 55.6% and 22.2% in population three, p < 0.001; 100%, 60% and 20% in population
four, p = 0.036. EORTC/MSG European Organization for the Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group; ICU Intensive Care Unit; *: P< 0.05
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The proposed criterion for IPA in critically Ill COPD patients
admitted to the ICU
Modified criteria for defining probable IPA based on the
Bulpa criteria are proposed mainly based a revised inter-
pretation of the requirements regarding microbiological
findings (Table 4).
Probable IPA can be diagnosed when a critically ill
COPD patient in the ICU exhibits a pulmonary func-
tional level of GOLD III or IV, a history of steroid
use of at least 3 months (irrespective of administra-
tion route and dose/ course) and appropriate compat-
ible signs or symptoms, the presence of any major
radiological sign of pneumonia and one of the men-
tioned microbiological findings.
Discussion
To the best of our knowledge, the current study is the
first to compare the validity of diagnosis between the
existed three criteria commonly used for IPA. The major
power of this study was that we evaluated the “diagnos-
tic rate” of probable IPA in different populations, and
validated the results based on a proven population.
The major finding of this study is that we verified that
Bulpa criteria was the most suitable criteria for IPA diag-
nosis in critically ill COPD patients admitted to ICU
compared with the other two. While the defects in
microbiological findings still existed in Bulpa criteria,
the modified Bulpa criteria for probable IPA were pro-
posed and will need further verification by comparing
Fig. 2 Comparison between the EORTC/ MSG and Bulpa criteria. We found that all probable IPA diagnosed by the EORTC/ MSG criteria were also
diagnosed by the Bulpa criteria; 16 (80%) patients who were not classified by EORTC could be diagnosed as probable IPA by the Bulpa criteria,
and the remaining 4 (20%) patients remained non-classified even based on the Bulpa criteria
Fig. 3 Comparison between the ICU and Bulpa criteria. We found that all cases that were diagnosed as probable IPA by the ICU criteria were also
diagnosed by the Bulpa criteria; 10 (71.4%) cases that were not classified by ICU were diagnosed as probable IPA by the Bulpa criteria, and the
remaining 4 (28.6%) patients remained non-classified even based on the Bulpa criteria
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against proven IPA cases in the future studies. Further-
more, We analyzed reasons for the highest “diagnostic
rate” in Bulpa criteria.
We found that many non-classified patients by
EORTC/ MSG and ICU criteria could be diagnosed as
probable IPA by Bulpa criteria. Bulpa criteria made less
strict requirements in dose/ course of steroid and typical
CT manifestations, thus improving the“ diagnostic rate”.
As reported, almost 30-70% of IPA patients in an ICU
were not in a severely immunocompromised condition
[16, 17]. Most COPD patients lack the host factors that
are required by the EORTC/ MSG and ICU criteria with
the exception of steroid usage. In addition, although
Fig. 4 Comparison between the EORTC/ MSG and ICU criteria. We found that only 1 (25%) case that was diagnosed as probable IPA based on
the EORTC/ MSG criteria was diagnosed by the ICU criteria, and the remaining 3 (75%) cases were not classified; 9 (45%) cases that were not classified
by EORTC/ MSG were diagnosed as probable IPA based on the ICU criteria, and the remaining 11 (55%) patients remained non-classified even by the
ICU criteria
Table 3 Reasons for the non-classification of patients by the










Dose of steroid 0 (0%) 0 (0%) 9 (64.3%)
Course of steroid 6 (30%) 0 (0%) 0 (0%)
Dose and course of steroid 2 (10%) 0 (0%) 0 (0%)
Typical CT findings 1 (5%) 0 (0%) 0 (0%)
Steroid and CT 11 (55%) 0 (0%) 0 (0%)
BALF GM 0 (0%) 4 (100%) 0 (0%)
Positive LRTs culture 0 (0%) 0 (0%) 1 (7.1%)
Steroid and LRTs culture 0 (0%) 0 (0%) 4 (28.6%)
Note: the non-classification of patients by each criteria were listed above; the
main reasons were the strict requirements regarding steroid use, typical CT
findings and positive LRTs cultures
EORTC/MSG European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group; ICU Intensive Care Unit;
CT Computed Tomography; BALF Bronchoalveolar Lavage Fluid; GM
Galactomannan; LRT Lower respiratory tract
Table 4 Modified Bulpa criteria for probable IPA in critically Ill
COPD patients admitted to an ICU
Criteria for diagnosing probable IPA in critically ill COPD patients admitted
to ICU
1. Host factors ( the following at the same time)
i) Pulmonary function: A level of GOLD III or IV
ii) Steroid: treated with systemic steroid use, with no specific requirement
regarding dose or course; or treated with an inhaled steroid for at least
3 months
2. Compatible Signs or Symptoms (one of the following)
i) Fever refractory to at least three days of appropriate antibiotic therapy
ii) Recrudescent fever after a period of defervescence at least 48 h
while still on antibiotics and without other apparent cause
iii) Recent dyspnea or hemoptysis
iv) Worsening respiratory insufficiency despite appropriate therapy
and ventilator support
3. Radiological Findings (one of the following)
Abnormal imaging on CT or X-ray, within three month
i) Nonspecific infiltrates and patchiness
ii) Multiple nodules distributed along the airway





4. Mycological Data (one of the following)
i) Positive culture and/or microscopy for Aspergillus from LRTs
ii) Two consecutive positive serum/BALF GM tests*,#
iii) One positive BALF test and one positive serum GM test
*,#: A serum galactomannan test greater than 0.5 ng/ml and BALF galactomannan
test greater than 0.8 ng/ml were defined as a positive result
Note: The diagnose of probable IPA could be made when a critically ill COPD
patients in ICU with a pulmonary functional level of GOLD III or IV, a history of
steroid use for at least 3 months and appropriate compatible signs or symptoms,
having any major radiological sign of pneumonia and one of the
microbiological findings.
IPA Invasive Pulmonary Aspergillus; COPD Chronic Obstructive Pulmonary
Disease; ICU Intensive Care Unit; GOLD Global Initiative for Chronic Obstructive
Lung Disease; CT Computed Tomography; LRT Lower Respiratory Tract; BALF
Bronchoalveolar Lavage Fluid; GM Galactomannan
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precise doses and courses of steroid cannot be extrapo-
lated from the literature for COPD patients, data sup-
port the fact that patients with underlying lung diseases
are at risk for IPA at much lower doses and shorter
courses [1, 4, 5, 18–21]. Recently, some reports have
suggested that high doses of inhaled corticosteroids may
also be a risk factor for IPA [22–24], and some COPD
patients might develop IPA even without exposure to
steroids [25]. Thus, in the clinical practice, there is no
need for the excessively strict requirements regarding
the dose and course of systemic steroid use, and the in-
haled steroid should also be contained.
Nonspecific manifestations, such as patchiness or con-
solidations, are more frequently in COPD patients. The
research of Meersseman W [26] and Vandewoude K [9]
reported that the halo signs only appeared in 5-17%
cases of COPD that are complicated with IPA. Our re-
search [27] also demonstrated that patchiness (76.2%)
were the most common CT sign among IPA in critically
ill COPD patients admitted to ICU, while the angio-
invasive patterns (including halo sign, wedge consoli-
dation and air-crescent sign/ cavity) had a relatively
low percent. Therefore, there is no need for the ex-
cessively strict requirements in typical CT manifesta-
tions as well in diagnostic criteria for IPA in critically
ill COPD patient.
Defects in microbiological findings existed in Bulpa
criteria. The lack of BALF GM tests in mycological data
was the deficiency of the Bulpa criteria, which might
underestimate some IPA patients. Our previous study
[15] showed that positive BALF GM was observed earl-
ier than that in LRT secretion culture (1 day versus
3.8 days), and an appropriate cut-off value enabled the
discrimination of infection from colonization with
Aspergillus. Therefore, the two consecutive positive
BALF GM tests were found useful in diagnosing cases of
probable IPA, and should be added into Bulpa criteria.
Besides, positive serum antibody test for A. fumigatus
(including precipitins) is included in the Bulpa criteria;
however, it takes at least 3-6 months to elicit an anti-
body response [8, 28, 29], and the course of acute IPA is
too rapid compared to antibody formation. Moreover,
the antibody response is often weak in severe COPD pa-
tients on long-term steroid therapy [8]. Serum antibody
testing for A. fumigatus, including that based on precipi-
tins is an extremely useful technique in patients with
chronic pulmonary aspergillosis (CPA) [8, 29, 30], and
the use of this test in clinical practice is far from univer-
sal, so it should be removed from the Bulpa criteria.
We also noticed that the semi-quantitative Aspergillus-
positive culture of BALF, without bacterial growth but
with a positive cytological smear showing branching hy-
phae, is included in the ICU criteria as an alternative
item for host factors; nevertheless, mixed infections with
bacteria are common in critically ill COPD patients in
the ICU; therefore, it was not appropriate to add it to
Bulpa criteria as an alternative item for host factors.
There were several limitations in our study. The great-
est one was the small number (only 5) of proven IPA
cases in our study, for which histopathological speci-
mens were available to verify the validity of the clinical
assumption, thus we could only estimate the “diagnostic
rate” of probable IPA cases in population one, two and
three, and observed the consistency of the results with
those for the proven IPA group, leading to weak persua-
siveness. Moreover, it may also have a problem in over-
estimating the number of IPA based on Bulpa criteria;
however, a delayed diagnosis was associated with a worse
prognosis, we would rather accept a diagnose criteria
with a lower missed diagnostic rate. Third, the sample
size was relatively small because of the strict inclusion
criteria, which included critically ill COPD patients in an
ICU with a pulmonary functional level of GOLD III or
IV, and the availability of CTs obtained within a short
period. The above limitations require further investigations.
Conclusion
Among the existing three criteria, the Bulpa criteria are
the most suitable for diagnosing probable IPA in critic-
ally ill COPD patients admitted to ICU. The modified
Bulpa criteria for probable IPA was proposed and needs
further confirmation,
Additional file
Additional file 1: “Three Key Factors” of the Included Patients. Note: The
history of steroid use, abnormal radiology and mycological findings of
the included 59 COPD patients were listed in Additional file 1, and patients
were diagnosed as probable IPA using three criteria respectively. “Y” means
that the case was could be diagnosed as probable/ putative IPA according
to the criteria; “N” means that the case was could not be diagnosed as
probable/ putative IPA according to the criteria. (DOCX 128 kb)
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